Research ExplorerPublicationsMetastasiertes kastrationsresistentes Prostatakarzinom

Metastasiertes kastrationsresistentes Prostatakarzinom

Standard

Metastasiertes kastrationsresistentes Prostatakarzinom : Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage. / Gschwend, J E; Albers, P; Bögemann, M; Goebell, P; Heidenreich, A; Klier, J; König, F; Machtens, S; Pantel, K; Thomas, C.

In: UROLOGE, Vol. 57, No. 1, 01.2018, p. 34-39.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Gschwend, JE, Albers, P, Bögemann, M, Goebell, P, Heidenreich, A, Klier, J, König, F, Machtens, S, Pantel, K & Thomas, C 2018, 'Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage', UROLOGE, vol. 57, no. 1, pp. 34-39. https://doi.org/10.1007/s00120-017-0533-y

APA

Gschwend, J. E., Albers, P., Bögemann, M., Goebell, P., Heidenreich, A., Klier, J., König, F., Machtens, S., Pantel, K., & Thomas, C. (2018). Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage. UROLOGE, 57(1), 34-39. https://doi.org/10.1007/s00120-017-0533-y

Vancouver

Gschwend JE, Albers P, Bögemann M, Goebell P, Heidenreich A, Klier J et al. Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage. UROLOGE. 2018 Jan;57(1):34-39. https://doi.org/10.1007/s00120-017-0533-y

Bibtex

@article{a8dc9cc2558c48e98ad08e05e51c82e2,
title = "Metastasiertes kastrationsresistentes Prostatakarzinom: Neues zu Cabazitaxel unter Ber{\"u}cksichtigung der aktuellen Datenlage",
abstract = "BACKGROUND: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.OBJECTIVES: The focus is on the clinical impact of these data.MATERIALS AND METHODS: A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.RESULTS: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.CONCLUSIONS: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.",
keywords = "English Abstract, Journal Article",
author = "Gschwend, {J E} and P Albers and M B{\"o}gemann and P Goebell and A Heidenreich and J Klier and F K{\"o}nig and S Machtens and K Pantel and C Thomas",
year = "2018",
month = jan,
doi = "10.1007/s00120-017-0533-y",
language = "Deutsch",
volume = "57",
pages = "34--39",
journal = "UROLOGE",
issn = "0340-2592",
publisher = "Springer",
number = "1",

}

RIS

TY - JOUR

T1 - Metastasiertes kastrationsresistentes Prostatakarzinom

T2 - Neues zu Cabazitaxel unter Berücksichtigung der aktuellen Datenlage

AU - Gschwend, J E

AU - Albers, P

AU - Bögemann, M

AU - Goebell, P

AU - Heidenreich, A

AU - Klier, J

AU - König, F

AU - Machtens, S

AU - Pantel, K

AU - Thomas, C

PY - 2018/1

Y1 - 2018/1

N2 - BACKGROUND: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.OBJECTIVES: The focus is on the clinical impact of these data.MATERIALS AND METHODS: A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.RESULTS: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.CONCLUSIONS: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.

AB - BACKGROUND: At the 2016 ASCO annual meeting, new data from two randomized phase III studies concerning taxane-based chemotherapy as a treatment option for patients with metastatic castration-resistant prostate cancer (mCRPC) were presented.OBJECTIVES: The focus is on the clinical impact of these data.MATERIALS AND METHODS: A group of German experts in the field of urogenital-oncologic expertise discussed the clinical impact with respect to the current data.RESULTS: The study results support the current clinical data. They confirm the efficacy and safety of cabazitaxel beyond first-line therapy with docetaxel for patients with mCRPC.CONCLUSIONS: Cabazitaxel is an important treatment option after docetaxel progression. With respect to the performance status of a patient, it is adequate to reduce the dosage to 20 mg/m2 cabazitaxel.

KW - English Abstract

KW - Journal Article

U2 - 10.1007/s00120-017-0533-y

DO - 10.1007/s00120-017-0533-y

M3 - SCORING: Zeitschriftenaufsatz

C2 - 29071398

VL - 57

SP - 34

EP - 39

JO - UROLOGE

JF - UROLOGE

SN - 0340-2592

IS - 1

ER -